StockNews.com Begins Coverage on Chimerix (NASDAQ:CMRX)

StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX - Free Report) in a report published on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush restated a "neutral" rating and set a $8.55 target price (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $8.55 price target (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Trading Up 0.1 %

CMRX traded up $0.01 during trading hours on Monday, hitting $8.53. 1,013,325 shares of the company's stock were exchanged, compared to its average volume of 2,141,998. The firm has a market cap of $800.15 million, a P/E ratio of -9.07 and a beta of -0.18. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.53. The firm has a 50 day moving average of $6.22 and a 200 day moving average of $3.30.

Chimerix (NASDAQ:CMRX - Get Free Report) last posted its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. As a group, research analysts expect that Chimerix will post -0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 20,760 shares of company stock valued at $91,175 in the last ninety days. Insiders own 13.10% of the company's stock.

Institutional Trading of Chimerix

Several institutional investors have recently modified their holdings of CMRX. Bender Robert & Associates acquired a new stake in Chimerix during the 4th quarter worth $37,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Chimerix during the fourth quarter worth about $59,000. Jane Street Group LLC acquired a new stake in shares of Chimerix during the fourth quarter worth about $62,000. Diadema Partners LP acquired a new stake in shares of Chimerix during the fourth quarter worth about $101,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Chimerix in the 4th quarter valued at about $130,000. Hedge funds and other institutional investors own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.